WO2001096611A1 - Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida - Google Patents

Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida Download PDF

Info

Publication number
WO2001096611A1
WO2001096611A1 PCT/US2001/018882 US0118882W WO0196611A1 WO 2001096611 A1 WO2001096611 A1 WO 2001096611A1 US 0118882 W US0118882 W US 0118882W WO 0196611 A1 WO0196611 A1 WO 0196611A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
patient
codon
indicator
encodes
Prior art date
Application number
PCT/US2001/018882
Other languages
English (en)
Inventor
Jeannette Whitcomb
Original Assignee
Virologic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic, Inc. filed Critical Virologic, Inc.
Priority to BR0111575-8A priority Critical patent/BR0111575A/pt
Priority to AU2001266863A priority patent/AU2001266863A1/en
Priority to JP2002510724A priority patent/JP2004503253A/ja
Priority to CA002411401A priority patent/CA2411401A1/fr
Priority to EP01944452A priority patent/EP1292712A4/fr
Publication of WO2001096611A1 publication Critical patent/WO2001096611A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to antiretroviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) .
  • the invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
  • the invention also relates to novel vectors, host cells and compositions for carrying out phenotypic susceptibility tests.
  • the invention further relates to the use of various genotypic methodologies to identify patients whose infection has become less susceptible (“resistant”) to a particular antiretroviral drug regimen.
  • This invention also relates to the screening of candidate antiretroviral drugs for their capacity to inhibit viruses, selected viral sequences and/or viral proteins. More particularly, this invention relates to using phenotypic susceptibility tests and/or genotypic tests to identify patients whose virus/viruses exhibit drug-dependent stimulation of replication in the presence of anti-retroviral agents.
  • HIV infection is characterized by high rates of viral turnover throughout the disease process, eventually leading to CD4 depletion and disease progression (Wei X, Ghosh SK, Taylor ME, et al . (1995) Nature 343, 117-122) (Ho DD, Naumann AU, Perelson AS, et al . (1995) Nature 373, 123- 126) .
  • the aim of antiretroviral therapy is to achieve substantial and prolonged suppression of viral replication. Achieving sustained viral control is likely to involve the use of sequential therapies, generally each therapy comprising combinations of three or more antiretroviral drugs. Choice of initial and subsequent therapy should, therefore, be made on a rational basis, with knowledge of resistance and cross-resistance patterns being vital to guiding those decisions.
  • the primary rationale of combination therapy relates to synergistic or additive activity to achieve greater inhibition of viral replication.
  • the tolerability of drug regimens will remain critical, however, as therapy will need to be maintained over many years .
  • the target enzyme For antiretroviral drug resistance to occur, the target enzyme must be modified while preserving its function in the presence of the inhibitor. Point mutations leading to an amino acid substitution may result in changes in shape, size, or charge of the active site, substrate binding site, or surrounding regions of the enzyme. Mutants resistant to antiretroviral agents have been detected at low levels before the initiation of therapy (Mohri H, Singh MK, Ching WTW, et al.
  • a mutation or mutations that results in virus that can not only replicate in the presence of drug (i.e. resistant virus) but could actually replicate more efficiently in the presence of drug than in the absence of drug (i.e. drug-dependent stimulation of virus) would present an especially important phenotype to identify. In this case, a drug could actually accelerate the rate of destruction to the immune system and progression of disease.
  • NRTIs Non-nucleoside Reverse Transcriptase Inhibitors
  • Non-nucleoside reverse transcriptase inhibitors are a chemically diverse group of compounds which are potent inhibitors of HIV-1 Reverse Transcriptase (RT) in vitro.
  • These compounds include pyridinone derivatives, bis (heteroaryl) piperazines (BHAPs) such as delavirdine and atevirdine, the dipyridodiazepinone (nevirapine) , the thymine derivative groups (TSAO and HEPT) , an a-anilino phenylacetamide (a-APA) compound (loviride) , the quinoxaline-class inhibitors (HBY-097) , the benzodiazepin- one and -thione (TIBO) compounds, and the pyridinone derivatives (L-697,661).
  • BHAPs bis (heteroaryl) piperazines
  • a-APA a-anilino phenylacetamide
  • HBY-097 quinoxaline-class inhibitors
  • NNRTIs Three NNRTIs: nevirapine (NVP, Viramune, Boehringer Ingelhei , Ingelheim am Rhein, Germany) , delavirdine (DLV, Rescriptor, Pharmacia & Upjohn, Kalamazoo, MI, USA) , and efavirenz (EFV, Sustiva, Dupont, Wilmington, DE, USA) are licensed for use in the USA.
  • NNP Viramune, Boehringer Ingelhei , Ingelheim am Rhein, Germany
  • DLV delavirdine
  • EMV efavirenz
  • NNRTI binding pocket is a hydrophobic non-substrate binding region of RT where these agents directly interact with RT.
  • TSAO also has limited activity in the presence of the Y181C mutation, but maintains activity in the presence of mutations HIV RT at codons 100 and 103, and in vi tro selects for a unique mutation, GLU 138 aLys (E138K) , in the region where it most closely interacts with RT (Richman, DD, Ibid) (Richman DD, Shih C- K, Lowy I, et al . (1991) Proc Natl Acad Sci USA 88, 11241- 11245) .
  • loviride when used as monotherapy develops in most patients by week 24. It has been mapped to a range of HIV RT codons 100-110; 181-190), most commonly codon 103 (Staszewski S, Miller V, Kober A, et al . (1996) Antiviral Ther 1, 42-50) .
  • variants at codons 98 and 103 were the most frequent mutations detected at 24 weeks (Staszewski S, Miller V, Rehmet S, et al .
  • This mutation at codon 236 has been observed in clinical isolates during atevirdine therapy, although other resistance-conferring mutations at codons 103 and 181 have been reported during monotherapy as well as at codons 101, 188, 233 and 238 during combination therapy with zidovudine.
  • HBY-097 may initially select for a mutation at HIV RT codon 190 in vi tro, further passage consistently selects for mutations at HIV RT codons 74 and 75, with some mutant viruses showing decreased sensitivity to didanosine and stavudine, but not zidovudine (Kleim J-P, R ⁇ sner M, Winkler I, et al . (1995) J " Acquir Immune Defic Syndr 10 Suppl 3, 2) .
  • Efavirenz was introduced as a second generation NNRTI relatively recently.
  • Efavirenz has a unique profile in that it retains activity against viruses containing the common RT mutation, Y181C.
  • vi tro efavirenz selects for mutations at codons 100, 101, 103, 108, 179, 181, and 188. This is similar to the in vivo resistance profile, which includes mutations at codons 100, 103, 108, 190 and 225, (and possibly 101, 179, 181 and 188).
  • Winslow DL Garber S, Reid C, it al . Fourth International Antiviral Therapy 1977; 1 (Suppl.1): 6.
  • NRTIs non-nucleoside reverse transcriptase inhibitors
  • Still another object of this invention is to provide a test and methods for evaluating the biological effectiveness of candidate drug compounds which act on specific viruses, viral genes and/or viral proteins particularly with respect to viral drug resistance associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) . It is also an object of this invention to provide the means and compositions for evaluating HIV antiretroviral drug resistance and susceptibility. Still another object of this invention is to provide a means of determining whether a candidate antiretroviral drug will cause increased or stimulated viral replication. This and other objects of this invention will be apparent from the specification as a whole.
  • the present invention relates to methods, using phenotypic and genotypic methods to monitor the clinical progression of human immunodeficiency virus infection and its response to antiviral therapy.
  • the invention is also based, in part, on the discovery that genetic changes in HIV reverse transcriptase (RT) , which confer resistance to antiretroviral therapy, may be rapidly determined directly from patient plasma HIV RNA using phenotypic or genotypic methods.
  • RT HIV reverse transcriptase
  • PCR PCR based assays.
  • methods evaluating viral nucleic acid or viral protein in the absence of an amplification step could utilize the teaching of this invention to monitor and/or modify antiretroviral therapy.
  • This invention is based in part on the discovery of a mutation at codon 230 either alone or in combination with a mutation at codon 103 or 181 of HIV RT in NNRTI inhibitor treated patients, in which the presence of the mutations correlates with decreased susceptibility to delavirdine, nevirapine and efavirenz, and with drug-dependent stimulation of viral replication in the presence of delavirdine, nevirapine or efavirenz.
  • the mutations were found in plasma HIV RNA after a period of time following initiation of therapy.
  • This invention is based in part on the discovery of a mutation at codon 230 in combination with mutations at codons 101, 103, 190, 221 and 238 of HIV RT in NNRTI treated patients, in which the presence of the mutations correlates with a decrease in susceptibility to delavirdine, nevirapine and efavirenz, and with drug-dependent stimulation of viral replication in the presence of delavirdine, nevirapine or efavirenz.
  • This invention is based in part on the discovery of a mutation at codon 241 of RT that was discovered to occur in
  • NNRTI -resistance mutations correlates with decreased susceptibility to delavirdine, nevirapine and efavirenz.
  • Resistance test vectors containing patient sequences with these mutations exhibited reduced susceptibility to delavirdine, nevirapine and efavirenz as well as drug dependent stimulation of replication in the presence of all three drugs.
  • This invention is based in part on the discovery of mutations at codon 245 of RT that was discovered to occur in NNRTI-treated patients.
  • the presence of the mutation at 245, in addition to other NNRTI-resistance mutations correlates with decreased susceptibility to delavirdine, nevirapine and efavirenz.
  • Resistance test vectors containing patient sequences with these mutations exhibited reduced susceptibility to delavirdine, nevirapine and efavirenz as well as drug dependent stimulation of replication in the presence of all three drugs.
  • V245E or T test vectors containing V245E or T in combination with mutations at 103 (K103N) and 135
  • This invention is based in part on the discovery of a mutation at codon 270 of RT that was discovered to occur in NNRTI-treated patients.
  • the presence of the mutation at 270 in addition to other NNRTI -resistance mutations correlates with decreased susceptibility to delavirdine, nevirapine and efavirenz, and drug-dependent stimulation of viral replication.
  • This invention is based in part on the discovery of a patient - derived segment containing multiple mutations at HIV RT codons 35, 67, 69, 70, 106, 189, 200, 202, 208, 211, 215, 218, 219, 221, 227, 228, 283, 284, 286, 293 and 297 of RT that was discovered in an NNRTI-treated patient.
  • Resistance test vectors containing patient sequences with these mutations exhibited reduced susceptibility to delavirdine, nevirapine and efavirenz as well as drug dependent stimulation of replication in the presence of all three drugs.
  • Figure 1 Resistance Test Vector. Schematic representations of the HIV-1 genome (top panel) and the resistance test vector (bottom panel) , comprising a patient derived segment and an indicator gene viral vector.
  • FIG. 1 Two Cell Assay. Schematic Representation of the Assay.
  • a resistance test vector is generated by cloning the patient-derived segment (PDS) into an indicator gene viral vector. Using defective PR and RT sequences, it was shown that luciferase activity is dependent on functional PR and RT.
  • the resistance test vector is co-transfected with an expression vector that produces amphotropic murine leukemia virus (MLV) envelope protein or other viral or cellular proteins, which enable infection.
  • MLV amphotropic murine leukemia virus
  • Pseudotyped viral particles are produced containing the protease (PR) and the reverse transcriptase (RT) gene products encoded by the patient- derived segment (PDS) . The particles are then harvested and used to infect fresh cells.
  • MMV amphotropic murine leukemia virus
  • the assay is performed in the absence of drug and in the presence of drug over a wide range of concentrations.
  • Protease PR inhibitors are added to the cells following transfection, and are thus present during particle maturation.
  • RT inhibitors are added to the cells at the time of, or prior to, viral particle infection. The amount of luciferase is determined and the percentage (%) inhibition is calculated at the different drug concentrations tested.
  • Figure 3 Examples of phenotypic drug susceptibility profiles. Data are analyzed by plotting the percent inhibition of luciferase activity vs. logio drug concentration. This plot is used to calculate the drug concentration that are required to inhibit virus replication by 50% (IC50) and by 95% (IC95) . Shifts in the inhibition curves towards higher drug concentrations are interpreted as evidence of decreased drug susceptibility, ("drug resistance"). Three typical curves for the NNRTI ' s delavirdine (DLV), nevirapine
  • NTP nefavirenz
  • EMV efavirenz
  • pre-treatment sample or as compared to a drug susceptible virus control, such as PNL4-3 or HXB-2.
  • a drug susceptible virus control such as PNL4-3 or HXB-2.
  • Figure 4 Examples of phenotypic drug susceptibility profiles showing drug-dependent stimulation of viral replication. Data are analyzed by plotting the percent inhibition of luciferase activity vs. logio drug concentration. This plot is used to calculate the drug concentration that are required to inhibit virus replication by 50% (IC50) and by 95% (IC95) . In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition) . Three typical curves showing drug-dependent stimulation of viral replication in the presence of the NNRTI 's delavirdine (DLV), nevirapine (NVP) and efavirenz (EFV) are shown.
  • DLV delavirdine
  • NNP nevirapine
  • EMV efavirenz
  • results obtained from the patient- derived or site-directed mutant resistance test vectors are compared to results obtained from a drug susceptible virus control, such as PNL4-3 or HXB-2.
  • Figure 5 Table of patient viruses containing mutations at HIV RT codon position 230, as described in Examples 3,
  • FIG. 6 Reduced susceptibility and drug-dependent stimulation of viral replication of three site-directed mutants: K103N, M230L, and K103N combined with K230L, as described in Example 4.
  • the results from each site- directed mutant are compared to each other, as well as to those results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2.
  • stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition).
  • Figure 7 Reduced susceptibility and drug-dependent stimulation of viral replication for three site-directed mutants: Y181C, M230L, and Y181C combined with K230L, as described in Example 3.
  • the results from each site- directed mutant for each NNRTI are compared to each other, as well as to those results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2.
  • stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition).
  • Figure 8 Reverse mutagenesis of HIV RT codon positions 241 and 277 in Patient 11073, as described in Example 6.
  • the top panel of the figure shows the graphs from the patient sample, which contains the V241S mutation. In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition) for all three NNRTIs (delavirdine, efavirenz, and nevirapine) .
  • the bottom panel shows the results of site-directed reversion of the mutation to 241V. In this graph, there is no longer negative inhibition
  • NNRTIs delavirdine, efavirenz, or nevirapine
  • FIG. 9 Susceptibility curves of two time-points separated by 32 weeks in the course of therapy of Patient 014451, as described in Example 7.
  • the top panel of the figure shows susceptibility curves from patient sample 014459, (week 0) .
  • the bottom panel shows susceptibility curves from patient sample 014451, (week 32) , which show both reduced susceptibility as well as drug-dependent stimulation of viral replication in the presence of all three NNRTIs, which coincides with the emergence of HIV RT mutations at codons 101, 106, and 190.
  • FIG. 11 Reverse mutagenesis of HIV RT codon positions 245, 270, 277, 292, 293, and 297 in Patient 010829, as described in Example 11. The results from each mutant are compared to results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2.
  • the top panel of the figure shows the graphs from the patient sample, containing the mutations at codon positions 245, 270, 277, 292, 293, and 297. In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition) for all three NNRTIs (delavirdine, efavirenz, and nevirapine) .
  • the second panel of graphs shows the site-directed reversion of the mutation at codon 245, followed by the reversion of the mutation at codon 270. Both single reverse mutants retain profiles consistent with drug-dependent stimulation of viral replication (negative inhibition) in the presence of any of the NNRTIs (delavirdine, efavirenz, or nevirapine) .
  • the bottom panel shows the reversion of HIV-RT mutations at codons 245, 270, 277, 292, 293, and 297.
  • FIG. 12 Reduced susceptibility and drug-dependent stimulation of viral replication in of a site-directed mutants with HIV RT mutations K103N, 135T, and V245T, as described in Example 13.
  • the results from each mutant are compared to results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2.
  • a drug susceptible virus control such as PNL4-3, or HXB-2.
  • mutations at each HIV RT codon position alone did not result in drug-dependent stimulation
  • the triple mutant exhibits drug-dependent stimulation for all three NNRTIs (delavirdine, efavirenz, or nevirapine), In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition).
  • FIG. 13 Reverse mutagenesis of HIV RT codon position 270 in Patient 13522 as described in Example 12. The results from each mutant are compared to results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2.
  • the top panel of the figure shows the graphs from the patient sample, containing the 1270S mutation. In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition) for all three NNRTIs (delavirdine, efavirenz, and nevirapine) .
  • the second panel of graphs shows the site-directed reversion of the mutation at codon 270.
  • NNRTIs delavirdine, efavirenz, or nevirapine
  • the site- directed mutant retains reduced drug susceptibility (drug resistance) to all three NNRTIs.
  • Figure 14 Table of clinical history of twelve viral samples from Patient 1033, as described in Example 14. Data include: drug regimen, duration of drug regimen, viral load, phenotypic fold-change in susceptibility values relative to a drug sensitive virus control, such as PNL4-3, or HXB-2, and percent negative inhibition for those samples exhibiting drug-dependent stimulation of virus production.
  • a drug sensitive virus control such as PNL4-3, or HXB-2
  • FIG. 14 Table of HIV-RT amino acid mutations for twelve viral samples from Patient 1033, as described in Example 14.
  • Figure 16 Effect of specific mutations on 1033-3 virus as discussed in Example 14, as determined by site- directed mutagenesis. The results from each mutant are compared to results obtained from a drug susceptible virus control, such as PNL4-3, or HXB-2. In these graphs, stimulation of viral replication manifests as percent inhibition less than zero (i.e. negative inhibition) .
  • Figure 17 Effect of M184V mutation on stimulation phenotype as described in Example 14, as .determined by site-directed mutagenesis. Reversion of the mutation at HIV RT codon 184 results in increasing levels of drug- dependent stimulation of viral replication, as manifested by percent inhibition less than zerO (i.e. negative inhibition) .
  • FIG. 18 Patient 014451, reduced susceptibility to NNRTI an drug dependent stimulation of viral replication associated with mutations at codon 101, codon 106 and codon 190 (Example 7) .
  • the present invention relates to methods of monitoring the clinical progression of HIV infection in patients receiving antiretroviral therapy, particularly non- nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral therapy, and to the detection of variants of HIV that exhibit drug-dependent stimulation of replication in the presence of one or more NNRTIs.
  • NRTI non- nucleoside reverse transcriptase inhibitor
  • the present invention provides for a method of assessing the effectiveness of antiretroviral therapy of a patient comprising (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding HIV RT having a mutation at one or more positions codon in the RT.
  • the mutation (s) correlate positively with changes in phenotypic susceptibility/resistance .
  • the invention provides for a method of assessing the effectiveness of NNRTI antiretroviral therapy of a patient comprising (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding HIV RT having a mutation at codon 230 and 103 or 181.
  • this invention established that mutations at codon 230, either alone or in combination with a mutation at codon 103 or 181 of HIV RT, correlate with a decreased susceptibility to delavirdine, nevirapine and efavirenz.
  • Patient derived resistance test vectors containing the mutation M230L show reductions in susceptibility that range from 10 -fold to >450-fold for delavirdine, from 5-fold to >250-fold for efavirenz, and from 10-fold to >600-fold for nevirapine.
  • the percent stimulation of viral replication in patient derived resistance test vectors containing mutations at codon 230 in HIV RT ranges from 0% to -100% for all three NNRTIs.
  • Site-directed resistance test vectors containing mutations at 230 either alone or in combination with 103 or 181 were constructed. The mutation at 230 alone causes reduced susceptibility to delavirdine (58-fold) , nevirapine (40-fold) and efavirenz
  • the combination of mutations at 230 and 103 causes reduced susceptibility to delavirdine (>250-fold) , nevirapine (>600-fold) and efavirenz (>470-fold) and drug-dependent stimulation of replication in the presence of delavirdine (-100%) nevirapine (-70%) , and efaviraenz (-40%) .
  • the combination of mutations at 230 and 181 causes reduced susceptibility to delavirdine (>250-fold) , nevirapine (>800-fold) and efavirenz (25 -fold) but no drug- dependent stimulation of replication in the presence of delavirdine, nevirapine, or efaviraenz.
  • the invention provides for a method of evaluating the effectiveness of NNRTI antiretroviral therapy of a patient comprising (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding HIV RT having a mutation at codon 241, 103 and 135 or at codon 241 in combination with mutations at 101, 106, 135, 138 and 190.
  • this invention established that mutations at codon 241, in combination with a mutation at codon 103, or mutations at 101, 106 and 190 of HIV RT are correlated with decreased susceptibility (increased resistance) to delavirdine, nevirapine and efavirenz.
  • NNRTI -resistance mutations (e.g. 101, 103, 106, 135, 138 and 190) displayed reductions in susceptibility ranging from 41-fold to >250-fold for delavirdine, and showed high level reductions in susceptibility to nevirapine (>600-fold) and efavirenz (>470-fold) .
  • Patient-derived resistance test vectors containing mutations at 241 in combination with other NNRTI-resistance mutations e.g. 101, 103, 106, 135, 138 and 190
  • displayed drug-dependent stimulation of viral replication ranging from 70 - 100% for all three NNRTIs.
  • the invention provides for a method of assessing the effectiveness of NNRTI antiretroviral therapy of a patient comprising (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding HIV RT having a mutation at codon 245, 103 and 135 or having a mutation at codon 245 in combination with additional mutations that could include 98, 101, 103, 135, 138, 181, 190 and/or 225.
  • this invention established that a mutation at codon 245 in combination with mutations at codons 103 and 135, or a mutation at codon 245 with additional mutations that may include 98, 101, 103, 135, 138, 181, 190 and 225 of HIV RT correlated with decreased susceptibility to delavirdine, nevirapine and efavirenz.
  • Patient-derived resistance test vectors containing mutations at 245 and additional NNRTI-resistance mutations as described above exhibited reductions in susceptibility ranging from 20- fold to >250-fold for delavirdine, from 8-fold to >600- fold for nevirapine and from 5-fold to >470-fold for efavirenz.
  • Patient-derived resistance test vectors containing mutations at 245 and additional NNRTI- resistance mutations as described above exhibited drug- dependent stimulation in viral replication ranging from 20 - 100% for all three NNRTIs.
  • Site-directed resistance test vectors were constructed containing mutations at 245, 103 and 135 and in various combinations as described above.
  • Mutations at HIV RT codon 245 (V245E or V245T) alone cause no significant reduction in susceptibility to delavirdine, nevirapine or efavirenz.
  • the combination of mutations at 245 (V245E) with 103 (K103N) and 135 (I135T) causes reduced susceptibility to delavirdine (169-fold) , nevirapine (244-fold) and efavirenz (93-fold) and drug- dependent stimulation of replication in the presence of delavirdine (-20%) and nevirapine (-15%) but not efavirenz.
  • the invention provides for a method of evaluating the effectiveness of NNRTI antiretroviral therapy of a patient comprising (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding HIV RT having a mutation at codon 270 and additional mutations at codons 103 and 135, with or without mutation at codon 225.
  • this invention established that mutation at codon 270 in combination with mutations at codon 103 and 135 with or without mutation at codon 225 of HIV RT are correlated with a decreased susceptibility to delavirdine, nevirapine, and efavirenz, and drug-dependent stimulation of replication in the presence of delavirdine, nevirapine and efavirenz.
  • Patient-derived resistance test vectors containing mutations at 270 in addition to other NNRTI-resistance mutations displayed high-level reductions in susceptibility to all three
  • NNRTIs and drug-dependent Stimulations in viral replication ranging from 80 - 110% for all three NNRTIs.
  • the phenotypic susceptibility/resistance profile and genotypic profile of the HIV virus infecting the patient has been altered, reflecting some change in the response to the antiretroviral agent.
  • the HIV virus infecting the patient may be resistant to any combination of the three NNRTIs described herein.
  • the virus may be found to replicate more efficiently in the presence of one or more drug(s) than in the absence of those drugs. It therefore may be desirable after detecting the mutation, to either increase the dosage of the antiretroviral agent, change to another antiretroviral agent, or add one or more additional antiretroviral agents to the patient's therapeutic regimen.
  • the patient ' s therapeutic regimen may desirably be altered by eliminating NNRTI antiretroviral agents, such as delavirdine, efavirenz or nevirapine; and/or (ii) adding another antiretroviral agent to the patient ' s therapeutic regimen.
  • NNRTI antiretroviral agents such as delavirdine, efavirenz or nevirapine
  • adding another antiretroviral agent may be evaluated by monitoring viral burden such as by HIV RNA copy number. A decrease in HIV RNA copy number correlates positively with the effectiveness of a treatment regimen.
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient- derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 230, 103 and 181; and (v) determining the presence or absence of mutations at codons 230, 103 and 181 from the sequences .
  • PDS patient- derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 230, 101, 103, 190, 221, and 238; and (v) determining the presence or absence of mutations at codons 230, 101, 103, 190, 221, and 238 from the sequences .
  • This invention also provides for a method of assessing the effectiveness of non nucleoside reverse transcriptase antiretroviral therapy of an HIV-infected patient comprising: (a) collecting a biological sample from an HIV-infected patient; and (b) evaluating whether the biological sample comprises nucleic acid encoding HIV reverse transcriptase having a mutation at codon 230 alone or in combination with a mutation at codon 103 or a mutation at codon 181, wherein the presence of such a mutation correlates with a decrease in non-nucleoside reverse transcriptase inhibitor susceptibility and drug- dependent stimulation of viral replication.
  • This invention also provides for a method for assessing the biological ef ectiveness of a candidate HIV antiretroviral drug compound comprising: (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 230 alone or in combination with a mutation at codon 103 or a mutation at codon 181 and an indicator gene into a host cell; (b) culturing the host cell from step (a); (c) measuring the expression of the indicator gene in a target host cell; and (d) comparing the measurement of the expression of the indicator gene from step (c) with the measurement of the expression of the indicator gene measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound; wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) (c) ; at steps (b) - (c) ; or at step (c) and wherein a decrease in expression of the indicator gene measured in the persence of the candidate anti
  • This invention provides for a resistance test vector comprising: (i) an HIV patient-derived segment which comprises reverse transcriptase having a mutation in at least one of codons 230, 103 or 181, and (ii) and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding
  • RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 241, 103 and 135; and (v) determining the presence or absence of mutations at codons 241, 103 and 135 from the sequences .
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 241, 101, 106, 135, 138, and 190; and (v) determining the presence or absence of mutations at codons 241, 101, 106, 135, 138, and 190 from the sequences .
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 98, 135 and 181; and (v) determining the presence or absence of mutations at codons 245, 98, 135 and 181 from the sequences.
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 101, 103, 135 and 190; and (v) determining the presence or absence of mutations at codons 245, 101, 103, 135, and 190 from the sequences.
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 103, 225, and 270; and (v) determining the presence or absence of mutations at codons 245, 103, 225 and 270 from the sequences.
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding
  • RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 135 and 138; and (v) determining the presence or absence of mutations at codons 245, 135 and 138 from the sequences .
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 98, 103, 135, 181, and 190; and (v) determining the presence or absence of mutations at codons 245, 98, 103, 135, 181, and 190 from the sequences .
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, and 103; and (v) determining the presence or absence of mutations at codons 245, and 103 from the sequences .
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 245, 103, 135 and 225; and (v) determining the presence or absence of mutations at codons 245, 103, 135 and 225 from the sequences.
  • PDS patient-derived segment
  • a method of assessing the effectiveness of NNRTI therapy of a patient comprising: (i) collecting a biological sample from an HIV-infected patient; (ii) transcribing the HIV-encoding RNA in the biological sample to cDNA; (iii) amplifying a patient-derived segment (PDS) using HIV PCR primers that result in a product comprising the RT gene; (iv) performing sequencing reactions using primers that yield sequences comprising wild type or mutant amino acids at codons 270, 103 and 135; and (v) determining the presence or absence of mutations at codons 270, 103 and 135 from the sequences .
  • PDS patient-derived segment
  • mutations at codons 230, 101, 103, 190, 221, and 238 of the HIV RT gene indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 230, 101, 103, 190, 221 and 238, reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 241, 103, and 135 of the HIV RT gene indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 241, 103, and 135 reduce drug susceptibility, and result in drug- dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 245, 98, 135, and 181 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 245, 98, 135, and 181 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 245, 101, 103, 135, and 190 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 245, 101, 103, 135, and 190 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 245, 135, and 138 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 245, 98, 103, 135, 181, and 190 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 245, 98, 103, 135, 181, and 190 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 245 and 103 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 245 and 103 reduce drug susceptibility, and result in dru -dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • 225 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 245, 103, 135, and 225 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • mutations at codons 270, 103, and 135 of the HIV RT indicates that the effectiveness of the current or prospective NNRTI therapy has been diminished.
  • mutations at codons 270, 103, and 135 reduce drug susceptibility, and result in drug-dependent stimulation of viral replication.
  • change in the NNRTI therapy would be indicated.
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having a mutation at codon 230 and either codon 103 or 181.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 230 and either 103 and 181 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • RT encodes leucine (L)
  • the mutated codon 103 encodes an asparagine (N)
  • the mutated codon 230 or HIV RT encodes leucine (L)
  • the mutated codon at 181 encodes a cysteine (C) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 230, 101, 103, 190, 221, and 238.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 230, 101, 103, 190, 221, and 238 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 230 of HIV RT encodes a leucine (L)
  • the mutated codon 101 encodes a glutamic acid (E)
  • the mutated codon 103 encodes an asparagine (N)
  • the mutated codon 190 encodes a serine (S)
  • the mutated codon 221 encodes a tyrosine (Y)
  • the mutated codon 238 encodes a threonine (T) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 241, 103, and 135.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 241, 103, and 135 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 241 of HIV RT encodes a serine (S)
  • the mutated codon 103 encodes an asparagine (N)
  • the mutated codon 135 encodes a threonine (T) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 241, 101, 106, 135, 138, and 190.
  • Using the phenotypic susceptibility assay it was observed that the presence of mutations at codons 241, 101, 106, 135, 138, and 190 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 241 of HIV RT encodes an isoleucine (I)
  • the mutated codon 101 encodes a glutamic acid (E)
  • the mutated codon 106 encodes an methionine (M)
  • the mutated codon 135 encodes a threonine (T)
  • the mutated codon 138 encodes an alanine (A)
  • the mutated codon 190 encodes an alanine (A) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 98, 135, and 181.
  • Using the phenotypic susceptibility assay it was observed that the presence of mutations at codons 245, 98, 135, and 181 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 245 of HIV RT encodes a glutamic acid (E)
  • the mutated codon 98 encodes a Glycine (G)
  • the mutated codon 135 encodes a threonine (T)
  • the mutated codon 181 encodes a cysteine (C) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 101, 103, 135, and 190.
  • Using the phenotypic susceptibility assay it was observed that the presence of mutations at codons 245, 101, 103, 135, and 190 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 245 of HIV RT encodes a glutamic acid (E)
  • the mutated codon 101 encodes a glutamic acid (E)
  • the mutated codon 103 encodes asparagine (N)
  • the mutated codon 135 encodes a threonine (T)
  • the mutated codon 190 encodes an alanine (A) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 103, 225, and 270.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 245, 103, 225, and 270 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 245 of HIV RT encodes a glutamic acid (E)
  • the mutated codon 103 encodes asparagine (N)
  • the mutated codon 225 encodes a histidine (H)
  • the mutated codon 270 encodes a methionine (M) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 135, and 138.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 245, 135, and 138 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 245 of HIV RT encodes a threonine (T)
  • the mutated codon 135 encodes a threonine (T)
  • the mutated codon 138 encodes an glycine (G) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 98, 103, 135, 181, and 190.
  • Using the phenotypic susceptibility assay it was observed that the presence of mutations at codons 245, 98, 103, 135, 181, and 190 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 245 of HIV RT encodes a threonine (T)
  • the mutated codon 98 encodes a glutamic acid (G)
  • the mutated codon 103 encodes a asparagine (N)
  • the mutated codon 135 encodes a threonine
  • the mutated codon 181 encodes a cysteine (C)
  • the mutated codon 190 encodes an alanine (A) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245 and 103.
  • the mutated codon 245 of HIV RT encodes a threonine (T)
  • the mutated codon 103 encodes a asparagine (N) .
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 103, 135, and 225.
  • the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 245, 103, 135, and 225.
  • the mutated codon 245 of HIV RT encodes a methionine .
  • M methionine
  • N asparagine
  • N mutated codon 135
  • a method of evaluating the effectiveness of antiretroviral therapy of an HIV- infected patient comprising: (i) collecting a biological sample from an HIV-infected patient; and (ii) determining whether the biological sample comprises nucleic acid encoding the HIV RT gene, and having mutations at codons 270, 103, and 135.
  • the phenotypic susceptibility assay it was observed that the presence of mutations at codons 270, 103, and 135 correlates positively with decreased susceptibility to delavirdine, nevirapine, and efavirenz and results in drug-dependent stimulation of viral replication.
  • the mutated codon 270 of HIV RT encodes a serine (S)
  • the mutated codon 103 encodes asparagine (N)
  • the mutated codon 135 encodes a threonine (T) .
  • This invention also provides the means and methods to use the resistance test vector comprising an HIV gene further comprising an NNRTI mutation for drug screening. More particularly, the invention describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 230 and either 103 or 181 for drug screening. The invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 230 and 101, 103, 190, 221, and 238. The invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 241, 103, and 135. The invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 241, 101, 106, 190, 135, and 138.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 98, 135, and 181.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 101, 103, 135, and 190.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 103, 225, and 270.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 135 and 138.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 98, 103, 135, 181, and 190.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245 and 103.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 245, 103, 135, and 225.
  • the invention also describes the resistance test vector comprising the HIV reverse transcriptase having mutations at codons 270, 103 and 135.
  • Retrovirally infected cells shed a membrane virus containing a diploid RNA genome .
  • the virus studded with an envelope glycoprotein (which serves to determine the host range of infectivity) , attaches to a cellular receptor in the plasma membrane of the cell to be infected. After receptor binding, the virus is internalized and uncoated as it passes through the cytoplasm of the host cell.
  • the reverse transcriptase molecules resident in the viral core drive the synthesis of the double-stranded DNA provirus, a synthesis that is primed by the binding of a tRNA molecule to the genomic viral RNA.
  • the double-stranded DNA provirus is subsequently integrated in the genome of the host cell, where it can serve as a transcriptional template for both mRNAs encoding viral proteins and virion genomic RNA, which will be packaged into viral core particles.
  • core particles move through the cytoplasm, attach to the inside of the plasma membrane of the newly infected cell, and bud, taking with them tracts of membrane containing the virally encoded envelope glycoprotein gene product . This cycle of infection - reverse transcription, transcription, translation, virion assembly, and budding - repeats itself over and over again as infection spreads.
  • the viral RNA and, as a result, the proviral DNA encode several cis-acting elements that are vital to the successful completion of the viral lifecycle.
  • the virion RNA carries the viral promoter at its 3' end. Replicative acrobatics place the viral promoter at the 5 ' end of the proviral genome as the genome is reverse transcribed. Just 3' to the 5' retroviral LTR lies the viral packaging site.
  • the retroviral lifecycle requires the presence of virally encoded transacting factors .
  • the viral-RNA-dependent DNA polymerase (pol ) -reverse transcriptase is also contained within the viral core and is vital to the viral life cycle in that it is responsible for the conversion of the genomic RNA to the integrative intermediate proviral DNA.
  • the viral envelope glycoprotein, env is required for viral attachment to the uninfected cell and for viral spread.
  • transactivators transcriptional trans-activating factors, so called transactivators, that can serve to modulate the level of transcription of the integrated parental provirus.
  • replication-competent Typically, replication-competent
  • non-defective viruses are self-contained in that they encode all of these trans-acting factors. Their defective counterparts are not self-contained.
  • a DNA virus such as a hepadnavirus
  • understanding the life cycle and viral genes required for infection is useful to the practice of this invention.
  • Replication of HBV uses an RNA intermediate template.
  • the first step in replication is the conversion of the asymmetric relaxed circle DNA (re-DNA) to covalently closed circle DNA (cccDNA) .
  • re-DNA asymmetric relaxed circle DNA
  • cccDNA covalently closed circle DNA
  • This process which occurs within the nucleus of infected liver cells, involves completion of the DNA positive-strand synthesis and ligation of the DNA ends.
  • the cccDNA is transcribed by the host RNA polymerase to generate a 3.5 kB RNA template (the pregenome) . This pregenome is complexed with protein in the viral core.
  • the third step involves the synthesis of the first negative-sense DNA strand by copying the pregenomic RNA using the virally encoded P protein reverse transcriptase.
  • the P protein also serves as the minus strand DNA primer.
  • the synthesis of the second positive-sense DNA strand occurs by copying the first DNA strand, using the P protein DNA polymerase activity and an oligomer of viral RNA as primer.
  • the pregenome also transcribes mRNA for the major structural core proteins.
  • Resistance Test Vector Host Cell - a packaging host cell transfected with a resistance test vector
  • Target Host Cell - a host cell to be infected by a resistance test vector viral particle produced by the resistance test vector host cell
  • Resistance Test vector means one or more vectors which taken together contain DNA or RNA comprising a patient-derived segment and an indicator gene.
  • the resistance test vector comprises more than one vector the patient-derived segment may be contained in one vector and the indicator gene in a different vector.
  • Such a resistance test vector comprising more than one vector is referred to herein as a resistance test vector system for purposes of clarity but is nevertheless understood to be a resistance test vector.
  • the DNA or RNA of a resistance test vector may thus be contained in one or more DNA or RNA molecules.
  • the resistance test vector is made by insertion of a patient-derived segment into an indicator gene viral vector.
  • the resistance test vector is made by insertion of a patient-derived segment into a packaging vector while the indicator gene is contained in a second vector, for example an indicator gene viral vector.
  • patient-derived segment refers to one or more viral segments obtained directly from a patient using various means, for example, molecular cloning or polymerase chain reaction (PCR) amplification of a population of patient-derived segments using viral DNA or complementary DNA (cDNA) prepared from viral RNA, present in the cells (e.g. peripheral blood mononuclear cells, PBMC) , serum or other bodily fluids of infected patients.
  • PCR polymerase chain reaction
  • viral segment refers to any functional viral sequence or viral gene encoding a gene product (e.g., a protein) that is the target of an anti-viral drug.
  • functional viral sequence refers to any nucleic acid sequence (DNA or
  • RNA with functional activity such as enhancers, promoters, polyadenylation sites, sites of action of trans-acting factors, such as tar and RRE, packaging sequences, integration sequences, or splicing sequences.
  • patient-derived segments corresponding to each said viral gene would be inserted in the resistance test vector.
  • patient-derived segments corresponding to each functional viral sequence or viral gene product would be inserted in the resistance test vector.
  • the patient-derived segments are inserted into unique restriction sites or specified locations, called patient sequence acceptor sites, in the indicator gene viral vector or for example, a packaging vector depending on the particular construction being used as described herein.
  • patient-derived segment encompasses segments derived from human and various animal species. Such species include, but are not limited to chimpanzees, horses, catties, cats and dogs.
  • Patient-derived segments can also be incorporated into resistance test vectors using any of several alternative cloning techniques. For example, cloning via the introduction of class II restriction sites into both the plasmid backbone and the patient-derived segments or by uracil DNA glycosylase primer cloning (refs) .
  • the patient-derived segment may be obtained by any method of molecular cloning or gene ampli ication, or modifications thereof, by introducing patient sequence acceptor sites, as described below, at the ends of the patient-derived segment to be introduced into the resistance test vector.
  • restriction sites corresponding to the patient-sequence acceptor sites can be incorporated at the ends of the primers used in the PCR reaction.
  • restriction sites can be incorporated at the ends of the primers used for first or second strand cDNA synthesis, or in a method such as primer-repair of DNA, whether cloned or uncloned DNA, said restriction sites can be incorporated into the primers used for the repair reaction.
  • the patient sequence acceptor sites and primers are designed to improve the representation of patient-derived segments. Sets of resistance test vectors having designed patient sequence acceptor sites provide representation of patient-derived segments that would be underrepresented in one resistance test vector alone.
  • Resistance test vectors are prepared by modifying an indicator gene viral vector (described below) by introducing patient sequence acceptor sites, amplifying or cloning patient-derived segments and inserting the amplified or cloned sequences precisely into indicator gene viral vectors at the patient sequence acceptor sites.
  • the resistance test vectors are constructed from indicator gene viral vectors which are in turn derived from genomic viral vectors or subgenomic viral vectors and an indicator gene cassette, each of which is described below. Resistance test vectors are then introduced into a host cell.
  • a resistance test vector (also referred to as a resistance test vector system) is prepared by introducing patient sequence acceptor sites into a packaging vector, amplifying or cloning patient-derived segments and inserting the amplified or cloned sequences precisely into the packaging vector at the patient sequence acceptor sites and co-transfecting this packaging vector with an indicator gene viral vector.
  • the resistance test vector may be introduced into packaging host cells together with packaging expression vectors, as defined below, to produce resistance test vector viral particles that are used in drug resistance and susceptibility tests that are referred to herein as a "particle-based test.”
  • the resistance test vector may be introduced into a host cell in the absence of packaging expression vectors to carry out a drug resistance and susceptibility test that is referred to herein as a "non-particle-based test.”
  • a "packaging expression vector” provides the factors, such as packaging proteins (e.g. structural proteins such as core and envelope polypeptides) , transacting factors, or genes required by replication-defective retrovirus or hepadnavirus .
  • a replication-competent viral genome is enfeebled in a manner such that it cannot replicate on its own.
  • the packaging expression vector can produce the trans-acting or missing genes required to rescue a defective viral genome present in a cell containing the enfeebled genome, the enfeebled genome cannot rescue itself.
  • “Indicator or indicator gene” refers to a nucleic acid encoding a protein, DNA or RNA structure that either directly or through a reaction gives rise to a measurable or noticeable aspect, e.g. a color or light of a measurable wavelength or in the case of DNA or RNA used as an indicator a change or generation of a specific DNA or RNA structure.
  • Preferred examples of an indicator gene is the E. coli lacZ gene which encodes beta-galactosidase, the luc gene which encodes luciferase either from, for example, Photonis pyralis (the firefly) or Renilla reniformis (the sea pansy) , the E.
  • indicator gene which encodes alkaline phosphatase, green fluorescent protein and the bacterial CAT gene which encodes chloramphenicol acetyltransferase .
  • Additional preferred examples of an indicator gene are secreted proteins or cell surface proteins that are readily measured by assay, such as radioimmunoassay (RIA) , or fluorescent activated cell sorting (FACS) , including, for example, growth factors, cytokines and cell surface antigens (e.g. growth hormone, 11-2 or CD4 , respectively) .
  • RIA radioimmunoassay
  • FACS fluorescent activated cell sorting
  • “Indicator gene” is understood to also include a selection gene, also referred to as a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase
  • DHFR thymidine kinase
  • hygromycin thymidine kinase
  • neomycin zeocin
  • the indicator gene and the patient-derived segment are discrete, i.e. distinct and separate genes.
  • a patient-derived segment may also be used as an indicator gene.
  • one of said viral genes may also serve as the indicator gene.
  • a viral protease gene may serve as an indicator gene by virtue of its ability to cleave a chromogenic substrate or its ability to activate an inactive zymogen which in turn cleaves a chromogenic substrate, giving rise in each case to a color reaction.
  • the indicator gene may be either
  • the indicator gene may be capable of being expressed in a "packaging host cell/resistance test vector host cell" as defined below, independent of the patient-derived segment, however the functional indicator gene could not be expressed in the target host cell, as defined below, without the production of functional resistance test vector particles and their effective infection of the target host cell.
  • the indicator gene cassette comprising control elements and a gene encoding an indicator protein, is inserted into the indicator gene viral vector with the same or opposite transcriptional orientation as the native or foreign enhancer/promoter of the viral vector.
  • Non-Functional Indicator Gene places the indicator gene and its promoter (a CMV IE enhancer/promoter) in the same or opposite transcriptional orientation as the HIV-LTR or HBV enhancer-promoter, respectively, or the CMV IE enhancer/promoter associated with the viral vector.
  • the indicator gene may be "non-functional" in that the indicator gene is not efficiently expressed in a packaging host cell transfected with the resistance test vector, which is then referred to a resistance test vector host cell, until it is converted into a functional indicator gene through the action of one or more of the patient-derived segment products.
  • An indicator gene is rendered non-functional through genetic manipulation according to this invention.
  • an indicator gene is rendered non-functional due to the location of the promoter, in that, although the promoter is in the same transcriptional orientation as the indicator gene, it follows rather than precedes the indicator gene coding sequence.
  • This misplaced promoter is referred to as a "permuted promoter.”
  • the orientation of the non-functional indicator gene is opposite to that of the native or foreign promoter/enhancer of the viral vector.
  • the coding sequence of the non-functional indicator gene can neither be transcribed by the permuted promoter nor by the viral promoters.
  • the non-functional indicator gene and its permuted promoter is rendered functional by the action of one or more of the viral proteins .
  • T7 promoter T7 phage RNA polymerase promoter
  • the indicator gene cannot be transcribed by the T7 promoter as the indicator gene cassette is positioned upstream of the T7 promoter.
  • the non-functional indicator gene in the resistance test vector is converted into a functional indicator gene by reverse transcriptase upon infection of the target cells, resulting from the repositioning of the T7 promoter, by copying from the 5' LTR to the 3' LTR, relative to the indicator gene coding region.
  • a nuclear T7 RNA polymerase expressed by the target cell transcribes the indicator gene.
  • a non-functional indicator gene with a permuted promoter places an enhancer-promoter region downstream or 3' of the indicator gene both having the same transcriptional orientation.
  • the indicator gene cannot be transcribed by the enhancer-promoter as the indicator gene cassette is positioned upstream.
  • the non- functional indicator gene in the resistance test vector is converted into a functional indicator gene by reverse transcription and circularization of the HBV indicator gene viral vector by the repositioning of the enhancer-promoter upstream relative to the indicator gene coding region.
  • a permuted promoter may be any eukaryotic or prokaryotic promoter which can be transcribed in the target host cell.
  • the promoter will be small in size to enable insertion in the viral genome without disturbing viral replication.
  • a promoter that is small in size and is capable of transcription by a single subunit RNA polymerase introduced into the target host cell such as a bacteriophage promoter, will be used. Examples of such bacteriophage promoters and their cognate RNA polymerases include those of phages T7, T3 and Sp6.
  • a nuclear localization sequence may be attached to the RNA polymerase to localize expression of the RNA polymerase to the nucleus where they may be needed to transcribed the repaired indicator gene.
  • Such an NLS may be obtained from any nuclear-transported protein such as the SV40 T antigen.
  • an internal ribosome entry site such as the EMC virus 5' untranslated region (UTR) may be added in front of the indicator gene, for translation of the transcripts which are generally uncapped.
  • the permuted promoter itself can be introduced at any position within the 5 ' LTR that is copied to the 3 ' LTR during reverse transcription so long as LTR function is not disrupted, preferably within the U5 and R portions of the LTR, and most preferably outside of functionally important and highly conserved regions of U5 and R.
  • the permuted promoter can be placed at any position that does not disrupt the cis acting elements that are necessary for HBV DNA replication. Blocking sequences may be added at the ends of the resistance test vector should there be inappropriate expression of the non-functional indicator gene due to transfection artifacts (DNA concatenation) .
  • such a blocking sequence may consist of a T7 transcriptional terminator, positioned to block readthrough transcription resulting from DNA concatenation, but not transcription resulting from repositioning of the permuted T7 promoter from the 5' LTR to the 3' LTR during reverse transcription.
  • an indicator gene is rendered non-functional due to the relative location of the 5' and 3' coding regions of the indicator gene, in that, the 3' coding region precedes rather than follows the 5' coding region.
  • This misplaced coding region is referred to as a "permuted coding region.”
  • the orientation of the non-functional indicator gene may be the same or opposite to that of the native or foreign promoter/enhancer of the viral vector, as mRNA coding for a functional indicator gene will be produced in the event of either orientation.
  • the non-functional indicator gene and its permuted coding region is rendered functional by the action of one or more of the patient-derived segment products.
  • a second example of a non-functional indicator gene with a permuted coding region in the case of HIV places a 5 ' indicator gene coding region with an associated promoter in the 3 ' LTR U3 region and a 3 ' indicator gene coding region in an upstream location of the HIV genome, with each coding region having the same transcriptional orientation as the viral LTRs.
  • the 5' and 3' coding regions may also have associated splice donor and acceptor sequences, respectively, which may be heterologous or artificial splicing signals.
  • the indicator gene cannot be functionally transcribed either by the associated promoter or viral promoters, as the permuted coding region prevents the formation of functionally spliced transcripts.
  • the non-functional indicator gene in the resistance test vector is converted into a functional indicator gene by reverse transcriptase upon infection of the target cells, resulting from the repositioning of the 5 ' and 3 ' indicator gene coding regions relative to one another, by copying of the 3 ' LTR to the 5' LTR. Following transcription by the promoter associated with the 5' coding region, RNA splicing can join the 5' and 3' coding regions to produce a functional indicator gene product.
  • a non-functional indicator gene with a permuted coding region in the case of HBV, places a 3 ' indicator gene coding region upstream or 5 ' of the enhancer-promoter and the 5 ' coding region of the indicator gene.
  • the transcriptional orientation of the indicator gene 5 ' and 3 ' coding regions are identical to one another, and the same as that of the indicator gene viral vector. However, as the indicator gene 5 ' and 3 ' coding regions are permuted in the resistance test vectors (i.e., the 5' coding region is downstream of the 3 ' coding region) , no mRNA is transcribed which can be spliced to generate a functional indicator gene coding region. Following reverse transcription and circularization of the indicator gene viral vector, the indicator gene 3 ' coding region is positioned downstream or 3 ' to the enhancer-promoter and 5' coding regions thus permitting the transcription of mRNA which can be spliced to generate a functional indicator gene coding region.
  • the indicator gene is rendered non-functional through use of an "inverted intron," i.e. an intron inserted into the coding sequence of the indicator gene with a transcriptional orientation opposite to that of the indicator gene.
  • the overall transcriptional orientation of the indicator gene cassette including its own, linked promoter is opposite to that of the viral control elements, while the orientation of the artificial intron is the same as the viral control elements. Transcription of the indicator gene by its own linked promoter does not lead to the production of functional transcripts as the inverted intron cannot be spliced in this orientation.
  • the indicator gene Transcription of the indicator gene by the viral control elements does, however, lead to the removal of the inverted intron by RNA splicing, although the indicator gene is still not functionally expressed as the resulting transcript has an antisense orientation.
  • the indicator gene can be functionally transcribed using its own linked promoter as the inverted intron has- been previously removed.
  • the indicator gene itself may contain its own functional promoter with the entire transcriptional unit oriented opposite to the viral control elements.
  • the non-functional indicator gene is in the wrong orientation to be transcribed by the viral control elements and it cannot be functionally transcribed by its own promoter, as the inverted intron cannot be properly excised by splicing.
  • transcription by the viral promoters results in the removal of the inverted intron by splicing.
  • the indicator gene can now be functionally transcribed by its own promoter.
  • the inverted intron consisting of a splice donor and acceptor site to remove the intron, is preferably located in the coding region of the indicator gene in order to disrupt translation of the indicator gene.
  • the splice donor and acceptor may be any splice donor and acceptor.
  • a preferred splice donor-receptor is the CMV IE splice donor and the splice acceptor of the second exon of the human alpha globin gene ("intron A”) .
  • indicator gene viral vector refers to a vector (s) comprising an indicator gene and its control elements and one or more viral genes.
  • the indicator gene viral vector is assembled from an indicator gene cassette and a "viral vector, " defined below.
  • the indicator gene viral vector may additionally include an enhancer, splicing signals, polyadenylation sequences, transcriptional terminators, or other regulatory sequences. Additionally the indicator gene viral vector may be functional or nonfunctional. In the event that the viral segments which are the target of the anti-viral drug are not included in the indicator gene viral vector they are provided in a second vector.
  • An "indicator gene cassette” comprises an indicator gene and control elements.
  • “Viral vector” refers to a vector comprising some or all of the following: viral genes encoding a gene product, control sequences, viral packaging sequences, and in the case of a retrovirus, integration sequences.
  • the viral vector may additionally include one or more viral segments one or more of which may be the target of an anti-viral drug.
  • Two examples of a viral vector which contain viral genes are referred to herein as an "genomic viral vector” and a “subgenomic viral vector.”
  • a “genomic viral vector” is a vector which may comprise a deletion of a one or more viral genes to render the virus replication incompetent, but which otherwise preserves the mRNA expression and processing characteristics of the complete virus.
  • the genomic viral vector comprises the HIV gag-pol , vif, vpr, tat, rev, vpu, and nef genes (some, most or all of env may be deleted) .
  • a "subgenomic viral vector” refers to a vector comprising the coding region of one or more viral genes which may encode the proteins that are the target (s) of the anti-viral drug.
  • a preferred embodiment is a subgenomic viral vector comprising the HIV gag-pol gene .
  • a preferred embodiment is a subgenomic viral vector comprising the
  • HBV P gene In the case of HIV, two examples of proviral clones used for viral vector construction are: HXB2 (Fisher et al . , (1986) Nature, 320, 367-371) and NL4-3,
  • HBV human immunodeficiency virus
  • the viral coding genes may be under the control of a native enhancer/promoter or a foreign viral or cellular enhancer/promoter.
  • a preferred embodiment for an HIV drug susceptibility and resistance test is to place the genomic or subgenomic viral coding regions under the control of the native enhancer/promoter of the HIV-LTR U3 region or the CMV immediate-early (IE) enhancer/promoter.
  • IE immediate-early
  • a preferred embodiment for an HBV drug susceptibility and resistance test is to place the genomic or subgenomic viral coding regions under the control of the CMV immediate-early (IE) enhancer/promoter.
  • IE immediate-early
  • said vector contains the patient sequence acceptor sites.
  • the patient-derived segments are inserted in the patient sequence acceptor site in the indicator gene viral vector which is then referred to as the resistance test vector, as described above .
  • Patient sequence acceptor sites are sites in a vector for insertion of patient-derived segments and said sites may be: 1) unique restriction sites introduced by site-directed mutagenesis into a vector; 2) naturally occurring unique restriction sites in the vector; or 3) selected sites into which a patient-derived segment may be inserted using alternative cloning methods (e.g. UDG cloning) .
  • the patient sequence acceptor site is introduced into the indicator gene viral vector.
  • the patient sequence acceptor sites are preferably located within or near the coding region of the viral protein which is the target of the anti-viral drug.
  • the viral sequences used for the introduction of patient sequence acceptor sites are preferably chosen so that no change, or a conservative change, is made in the amino acid coding sequence found at that position.
  • the patient sequence acceptor sites are located within a relatively conserved region of the viral genome to facilitate introduction of the patient-derived segments.
  • the patient sequence acceptor sites are located between functionally important genes or regulatory sequences.
  • Patient-sequence acceptor sites may be located at or near regions in the viral genome that are relatively conserved to permit priming by the primer used to introduce the corresponding restriction site into the patient-derived segment.
  • primers may be designed as degenerate pools to accommodate viral sequence heterogeneity, or may incorporate residues such as deoxyinosine (I) which have multiple base-pairing capabilities.
  • Sets of resistance test vectors having patient sequence acceptor sites that define the same or overlapping restriction site intervals may be used together in the drug resistance and susceptibility tests to provide representation of patlent-derived segments that contain internal restriction sites identical to a given patient sequence acceptor site, and would thus be underrepresented in either resistance test vector alone.
  • Suitable host cells are mammalian cells.
  • Preferred host cells are derived from human tissues and cells which are the principle targets of viral infection.
  • HIV include human cells such as human T cells, monocytes, macrophage, dendritic cells, Langerhans cells, hematopoeitic stem cells or precursor cells, and other cells.
  • suitable host cells include hepatoma cell lines (HepG2 , Huh 7), primary human hepatocytes, mammalian cells which can be- infected by pseudotyped HBV, and other cells.
  • Host cells will assure that the anti-viral drug will enter the cell efficiently and be converted by the cellular enzymatic machinery into the metabolically relevant form of the anti-viral inhibitor.
  • Host cells are referred to herein as a "packaging host cells,” “resistance test vector host cells, " or “target host cells.”
  • a "packaging host cell” refers to a host cell that provides the trans-acting factors and viral packaging proteins required by the replication defective viral vectors used herein, such as the resistance test vectors, to produce resistance test vector viral particles.
  • the packaging proteins may be provided for by the expression of viral genes contained within the resistance test vector itself, a packaging expression vector (s), or both.
  • a packaging host cell is a host cell which is transfected with one or more packaging expression vectors and when transfected with a resistance test vector is then referred to herein as a "resistance test vector host cell" and is sometimes referred to as a packaging host cell/resistance test vector host cell.
  • HIV include 293 human embryonic kidney cells (293,
  • a "target host cell” refers to a cell to be infected by resistance test vector viral particles produced by the resistance test vector host cell in which expression or inhibition of the indicator gene takes place.
  • Preferred host cells for use as target host cells include human T cell leukemia cell lines including Jurkat (ATCC T1B-152) , H9 (ATCC HTB-176) , CEM (ATCC CCL-119) , HUT78 (ATCC T1B-161) , and derivatives thereof.
  • Phenotypic drug susceptibility and resistance tests are carried out using the means and methods described in PCT International Application No. PCT/US97/01609, filed January 29, 1997 which is hereby incorporated by reference .
  • patient-derived segment (PDS) corresponding to the HIV protease (PR) and reverse transcriptase coding regions were either patient -derived segments amplified by the reverse transcription- polymerase chain reaction method (RT-PCR) using viral RNA isolated from viral particles present in the serum of HIV-infected individuals or were mutants of wild type HIV-1 made by site directed mutagenesis of a parental clone of resistance test vector DNA.
  • Isolation of viral RNA was performed using standard procedures (e.g. RNAgents Total RNA Isolation System, Promega, Madison WI or RNAzol, Tel-Test, Friendswood, TX) .
  • the RT-PCR protocol was divided into two steps .
  • a retroviral reverse transcriptase [e.g.
  • Moloney MuLV reverse transcriptase (Roche Molecular Systems, Inc., Branchburg, NJ) , or avian myeloblastosis virus (AMV) reverse transcriptase, (Boehringer Mannheim, Indianapolis, IN)] was used to transcribe viral RNA into cDNA.
  • the cDNA was then amplified using a thermostable DNA polymerase [e.g.
  • the primers, Apal primer (PDSApa) and AgeI primer (PDSAge) used to amplify the "test" patient-derived segments contained sequences resulting in Apal and Agel recognition sites being introduced into the 5 ' and 3 ' termini of the PCR product, respectively as described in PCT International Application No. PCT/US97/01609, filed January 29, 1997.
  • Resistance test vectors incorporating the "test" patient- derived segments were constructed as described in PCT International Application No. PCT/US97/01609, filed January 29, 1997, using an amplified DNA product of 1.5 kB prepared by RT-PCR using viral RNA as a template and oligonucleotides PDSApa (1) and PDSAge (2) as primers, followed by digestion with Apal and Agel ) or the isoschizimer PINAI .
  • the plasmid DNA corresponding to the resultant resistance test vector comprises a representative sample of the HIV viral quasi- species present in the serum of a given patient, many (>100) independent E. coli transformants obtained in the construction of a given resistance test vector were pooled and used for the preparation of plasmid DNA.
  • a packaging expression vector encoding an amphotrophic MuLV 4070A env gene product enables production in a resistance test vector host cell of resistance test vector viral particles which can efficiently infect human target cells. Resistance test vectors encoding all HIV genes with the exception of env were used to transfect a packaging host cell (once transfected, the host cell is referred to as a "resistance test vector host cell").
  • the packaging expression vector which encodes the amphotrophic MuLV 4070A env gene product is used with the resistance test vector to enable production in the resistance test vector host cell of infectious pseudotyped resistance test vector viral particles .
  • Resistance tests performed with resistance test vectors were carried out using packaging host and target host cells consisting of the human embryonic kidney cell line 293 (Cell Culture Facility, UC San Francisco, SF, CA) or the Jurkat leukemic T-cell line (Arthur Weiss, UC San Francisco, SF, CA) .
  • Resistance tests were carried out with resistance test vectors using two host cell types. Resistance test vector viral particles were produced by a first host cell
  • the resistance test vector host cell that was prepared by transfecting a packaging host cell with the resistance test vector and the packaging expression vector.
  • the resistance test vector viral particles were then used to infect a second host cell (the target host cell) in which the expression of the indicator gene is measured.
  • the resistance test vectors containing a functional luciferase gene cassette were constructed and host cells were transfected with the resistance test vector DNA.
  • the resistant test vectors contained patient-derived reverse transcriptase and protease sequences that were either susceptible or resistant to the antiretroviral agents, such as nucleoside reverse transcriptase inhibitors, (NRTIs) non-nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors.
  • the resistance test vector viral particles produced by transfecting the resistance test vector DNA into host cells, either in the presence or absence of PRIs, were used to infect target host cells grown either in the absence of NRTIs or NNRTIs, or in the presence of increasing concentrations of the drug.
  • the amount of luciferase activity produced in infected target host cells in the presence of varying concentrations of drug was compared to the amount of luciferase produced in infected target host cells in the absence of drug.
  • Drug resistance was measured as the amount of drug required to inhibit by 50% the luciferase activity detected in the absence of drug (inhibitory concentration 50%, IC50) .
  • the IC50 values were determined by plotting percent drug inhibition vs. loglO drug concentration. Stimulation of viral replication was measured as the percent increase in luciferase activity detected when infection occurs in the presence of drug as compared to in the absence of drug.
  • Host cells were seeded in 10 -cm-diameter dishes and were transfected several days after plating with resistance test vector plasmid DNA and the envelope expression vector. Transfections were performed using a calcium- phosphate precipitation procedure. The cell culture media containing the DNA precipitate was replaced with fresh medium, from one to 24 hours, after transfection. Cell culture media containing resistance test vector viral particles was harvested one to four days after transfection and was passed through a 0.45-mm filter before being used to infect target host cells, or being stored at -80°C. HIV capsid protein (p24) levels in the harvested cell culture media were determined by an EIA method as described by the manufacturer (SAIC; Frederick,
  • target cells (293 and 293/T) were plated in cell culture media.
  • Control infections were performed using cell culture media from mock transfections (no DNA) or transfections containing the resistance test vector plasmid DNA without the envelope expression plasmid.
  • cell lysis buffer Promega
  • Cell lysates were assayed for luciferase activity (Fig.3). The inhibitory effect of the drug was determined using the following equation:
  • % luciferase inhibition 1 - (RLUluc [drug] ⁇ RLUluc) x
  • RLUluc is the Relative Light Unit of luciferase activity in infected cells in the presence of drug
  • RLUluc is the Relative Light Unit of luciferase activity in infected cells in the absence of drug.
  • IC50 values were obtained from the sigmoidal curves that were generated from the data by plotting the percent inhibition of luciferase activity vs. the loglO drug concentration.
  • the drug inhibition curves are shown in Fig.3.
  • the percent luciferase stimulation is the negative of the % inhibition calculated using the formula above. Curves showing drug-dependent stimulation of viral replication are shown in Fig. 4.
  • Resistance test vectors are constructed as described in Example 1. Resistance test vectors, or clones derived from the resistance test vector pools, are tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs may comprise members of the classes known as nucleoside reverse transcriptase inhibitors (NRTIs) , non- nucleoside reverse transcriptase inhibitors (NNRTIs) , and protease inhibitors (PRIs) .
  • NRTIs nucleoside reverse transcriptase inhibitors
  • NRTIs non- nucleoside reverse transcriptase inhibitors
  • PRIs protease inhibitors
  • the panel of drugs can be expanded as new drugs or new drug targets become available.
  • An IC50 is determined for each resistance test vector pool for each drug tested.
  • the pattern of susceptibility to all of the drugs tested is examined and compared to known patterns of susceptibility.
  • the effect of drug on viral replication i.e. luciferase activity
  • a patient sample may be further examined for genotypic changes correlated with the pattern of susceptibility observed.
  • Resistance test vector DNAs are analyzed by any of the genotyping methods known to one of ordinaryt standing in the art (see PCT International Application No. PCT/US97/01609 , filed January 29, 1997) .
  • patient HIV sample sequences are determined using viral RNA purification, RT/PCR and ABI chain terminator automated sequencing. The sequence that is determined is compared to control sequences present in the database or is compared to a sample from the patient prior to initiation of therapy, if available. The genotype is examined for sequences that are different from the control or pre-treatment sequence and correlated to the observed phenotype .
  • Genotypic changes that are observed to correlate with changes in phenotypic patterns of drug susceptibility are evaluated by construction of resistance test vectors containing the specific mutation on a defined, wild-type (drug susceptible) genetic background. Mutations may be incorporated alone and/or in combination with other known drug resistance mutations that are thought to modulate the susceptibility of HIV to a certain drugs or class of drugs. Mutations are introduced into the resistance test vector through any of the widely known methods for site- directed mutagenesis. In one embodiment of this invention the mega-primer PCR method for site-directed mutagenesis is used (Sarkar G, Sommer SS. (1990) . Biotechniques 8:404-407).
  • a resistance test vector containing the specific mutation or group of mutations is then tested using the phenotypic susceptibility assay described above and the susceptibility profile is compared to that of a genetically defined wild-type (drug susceptible) resistance test vector which lacks the specific mutations. Observed changes in the pattern of phenotypic susceptibility to the antiretroviral drugs tested are attributed to the specific mutations introduced into the resistance test vector.
  • Resistance test vectors were constructed as described in Example 1 from virus samples obtained from an individual patient at three separate time points over a 16-week period. This patient had been previously treated with two NRTIs (didanosine and lamivudine) and a PRI indinavir. At the time the first sample (designated 98- 773) was obtained, the patient began taking a new antiviral regimen including an NRTI (abacavir) an NNRTI (nevirapine) and two PRI's (nelfinavir and saquinavir) (PRIs) . The second sample (98-1046) was obtained 8 weeks later and a third sample (98-887) was obtained 16 weeks later.
  • Viral load measurements showed that the patient experienced a transient reduction in viral load (at week 4) followed by a return to baseline viral load (-60,000 copies/ml) at weeks 8 and 16.
  • Isolation of viral RNA and RT/PCR was used to generate patient derived segments (PDSs) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT.
  • the PDS were inserted into an indicator gene viral vector to generate resistance test vectors designated RTV-773, RTV-1046 and RTV-887. These RTVs were then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs (zidovudine, lamivudine, Stavudine, didanosine, zalcitabine, and abacavir) , NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • NRTIs zidovudine, lamivudine, Stavudine, didanosine, zalcitabine, and abacavir
  • NNRTIs delavirdine, efavirenz and nevirapine
  • PRIs amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir
  • a pattern of susceptibility to the NNRTIs was observed for patient samples RTV-1046 and RTV-887, in which there was a moderate decrease (5-fold) in efavirenz susceptibility and a significant decrease in nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility.
  • RTV-773, RTV-1046 and RTV-887 DNA were analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence.
  • RTV-773 HIV-1
  • Mutations M41L, L74I, M184V, L210W and T215Y are associated with NRTI resistance.
  • the mutations R211K and T296S are known sequence polymorphisms found among different wild-type (drug- sensitive) variants of HIV. In RTV-1046 and RTV-887 two additional mutations appeared at 181 and 230.
  • the mutation Y181C has been previously shown to be associated with resistance to the NNRTIs nevirapine and delavirdine but not efavirenz.
  • the M230L mutation was introduced into a wild-type (drug sensitive) resistance test vector using the mega-primer method for site-directed mutagenesis (Sakar • and Sommar, Ibid.) .
  • the resulting resistance test vector containing the M230L mutation (M230L-RTV) was then tested using the phenotypic assay described earlier, and the results were compared to those determined using a genetically defined resistance test vector that was wild type at position 230.
  • the M230L-RTV displayed a moderate loss of susceptibility to efavirenz (23-fold), nevirapine (39-fold) and delavirdine (58 -fold) compared to a wild type control RTV.
  • the M230L-RTV showed a drug-dependent stimulation of viral replication in the presence of delavirdine ' (-50%) and nevirapine (-50%) but not efavirenz.
  • a resistance test vector containing the M230L mutation and the Y181C mutation (Y181C/M230L-RTV) was constructed and tested using the phenotypic assay described earlier and the results were compared to those
  • the Y181C/M230L-RTV displayed a moderate reduction in susceptibility to efavirenz (25- fold) , and high-level reductions in susceptibility to nevirapine (>600-fold) and delavirdine (>250-fold) compared to a wild type control RTV.
  • the Y181C/M230L-RTV showed no drug-dependent stimulation of viral replication in the presence of any of the NNRTIs.
  • Resistance test vectors were constructed as described in Example 1 from virus samples obtained from an individual patient at two separate time points over an 15-week period. This patient had been previously treated with two NRTIs (stavudine, laminvudine and a PRI nelfinavir) . At the time the first sample (designated 99-2-009089) was obtained, the patient began taking a new anti-viral regimen including two NRI's (zidovudine, lamivudine and an NNRTI) . A second sample (99-2-009839) was obtained 4 weeks when viral loads were undetectable, later and a third sample (99-2-010835) was obtained 15 weeks after baseline.
  • RTVs were then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested.
  • the pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • a pattern of susceptibility to the NNRTIs was observed for patient sample RTV-010835 in which there was a significant decrease in efavirenz (270- fold) , nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility.
  • RTV-009089, and RTV-010835 DNA were analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence.
  • RTV-009089 mutations were noted at positions 49, 102, 122, 169, 178, 184, 195, 200, 211, 245, 250, 275, 276, 277, 286, and 294 compared to the control sequence.
  • RTV-010835 additional mutations appeared at codons 103 and 230.
  • the mutation K103N has been previously shown to be associated with resistance to the NNRTIs nevirapine, delavirdine and efavirenz.
  • Site directed mutagenesis is used to confirm the role of specific mutations in phenotypic susceptibility to antiretroviral drugs in HIV
  • the M230L mutation was tested alone and is described in Example 3 above.
  • a resistance test vector containing the M230L mutation and the K103N mutation (K103N/M230L-RTV) was constructed and tested using the phenotypic assay described earlier, and the results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 103 and 230.
  • the K103N/M230L-RTV displayed high- level reductions in susceptibility to nevirapine (>600- fold) , efavirenz (>470-fold) and delavirdine (>250-fold) compared to a wild type control RTV.
  • the K103N/M230L-RTV also showed significant drug-dependent stimulation of viral replication in the presence of nevirapine (-70%) , efavirenz (-40%) and delavirdine (-100%) .
  • a resistance test vector containing the M230L, K103N and the M184V mutations was constructed and tested using the phenotypic assay described earlier and the results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 103, 184 and 230.
  • M184V mutation onto the K103N, M230L backbone results in a reversal of the drug-dependent stimulation of viral replication.
  • Resistance test vectors were constructed as described in Example 1 from virus samples obtained from an individual patient at two separate time points over a 48 -week period. This patient had been previously treated with four NRTIs (zidovudine, stavudine, didanosine, lamivudine, and a PRI nelfinavir. At the time the first sample (designated AA2919) was obtained, the patient began taking a new anti-viral regimen including two NRTIs
  • Efavirenz was added to the regimen after 9 weeks .
  • a second sample (00-2-012090) was obtained 48 weeks after the initiation of study when the viral load increased to 455.
  • Isolation of viral RNA and RT/PCR was used to generate patient derived segments (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT from all three samples.
  • the PDS were inserted into an indicator gene viral vector to generate resistance test vectors designated RTV-2919 and RTV-012090. These RTVs were then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of antiretroviral drugs comprised members of the classes known as NRTIs (zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV-2919 and RTV-012090 DNA were analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence.
  • RTV-2919 mutations were noted at HIV RT codons 67, 86, 102, 118, 122, 158, 162, 174, 177, 211, 214, 215, 272, 275, 276, 277, 278, 281, 286 and 293 compared to the control sequence.
  • RTV-012090 additional mutations appeared at codons 101, 103, 190 and 230.
  • the mutations K101E, K103N and G190S have been previously shown to be associated with resistance to the NNRTIs nevirapine, delavirdine and efavirenz.
  • the appearance of the mutations K101E, K103N, G190S and M230L are correlated with the significant drug-dependent stimulation of viral replication in response to all three NNRTIs.
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 011073. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of
  • the PDS was inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-011073.
  • RTV-011073 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs (zidovudine, lamivudine, stavudine, didanosine, zalcitabine and abacavir) , NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • a pattern of susceptibility to the NNRTIs was observed for patient RTV-011073 in which there was a sigificant decrease in efavirenz (>450-fold) , nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility and a significant drug-dependent stimulation of viral replication in the presence of nevirapine (-70%) , delavirdine (-90%) and efavirenz (-80%) .
  • RTV-011073 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-011073 mutations were noted at HIV RT codons 20, 67, 69, 70, 102, 103, 118, I135T, 162, 211, 214, 218, 219, 241 and 277 compared to the control sequence .
  • HIV-1 HIV Sequence Database Los Alamos, NM
  • the RTV-011073/241V/277T displayed high-level reductions in susceptibility to nevirapine (126-fold) , efavirenz (54-fold) and delavirdine (50-fold) compared to a wild type control RTV.
  • the RTV-011073/241V/277T showed no drug-dependent stimulation of viral replication in the presence of any NNRTI tested.
  • a resistance test vector containing all of the mutations present in RTV-011073 except for the V241S was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-011073.
  • RTV-011073/241V showed no drug-dependent stimulation of viral replication in the presence of any NNRTI tested. In this patient sample the correlation of drug-dependent stimulation of viral replication with the mutation at V241S is very striking.
  • a resistance test vector containing a single mutation at V241S was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a wild type control RTV.
  • the RTV-V241S displayed small reductions in susceptibility to nevirapine (9- fold) , efavirenz (3-fold) and delavirdine (6-fold) compared to a wild type control RTV.
  • the RTV-V241S showed drug-dependent stimulation of viral replication in the presence of nevirapine (-30%) , delavirdine (-25%) but no drug-dependent stimulation of viral replication in the presence of efavirenz.
  • Resistance test vectors were constructed as described in Example 1 from virus samples obtained from an individual patient at two separate time points separated by a 32- week period. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate patient derived segments (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT from all three samples. The PDS were inserted into an indicator gene viral vector to generate resistance test vectors designated RTV- 014459 and RTV- 014451. These RTVs were then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs. This panel of anti-
  • ⁇ retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV- 014459 and RTV- 014459 DNA were analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence.
  • RTV- 014459 mutations were noted at HIV RT 351, 41, 49, 83, 102, 123, 135, 138, 174, 177, 178, 184, 215, 241, 257, 261, 277, 286, 293 and 297 compared to the control NL4-3 sequence.
  • additional mutations appeared at codons 101, 106 and 190.
  • the mutations K101E, V106M and G190A have been previously shown to be associated with resistance to the NNRTIs nevirapine, delavirdine and efavirenz, but not with stimulation of viral replication.
  • the appearance of the mutations K101E, V106M and G190A on the specific genetic backbone present in this virus is correlated with the significant drug-dependent stimulation of viral replication in response to all three NNRTIs.
  • the results shown in Example 6 above suggest that the mutation V241I may contribute to the stimulation of viral replication seen in this virus.
  • Example 1 from a virus sample obtained from patient 005738.
  • the prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT from both samples .
  • PDS patient derived segment
  • the PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-005738.
  • RTV-005738 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV-005738 DNA was analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence.
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 007130. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-007130. RTV-007130 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • PDS patient derived segment
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV-007130 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-007130 mutations were noted at codons 67, 101, 102, 103, 122, 135, 162, 174, 184, 190, 208, 221, 245, 272, 277, 283, 293 compared to the control sequence .
  • HIV-1 HIV Sequence Database Los Alamos, NM
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 006782. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-006782. RTV-006782 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • PDS patient derived segment
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility. A pattern of susceptibility to the
  • NNRTIs was observed for patient RTV-007130 in which there was a small decrease in efavirenz (5-fold) , nevirapine
  • RTV-006782 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-006782 mutations were noted at HIV RT codons Q102K, D123E, I135T, E138A, C162S, G196E, I202V, V245T, R277K, T286A, V293I, P294T and E297K compared to the control sequence .
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 012123. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated
  • RTV-012123 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested.
  • the pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • a pattern of susceptibility to the NNRTIs was observed for patient RTV-012123 in which there was a significant decrease in efavirenz (>450-fold) , nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility, and a significant drug-dependent stimulation of viral replication in the presence of nevirapine (-20%) , delavirdine (-80%) and efavirenz (-70%) .
  • RTV-012123 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-012123 mutations were noted at HIV RT codons 20, 39, 41, 44, 60, 67, 98, 102, 103, 118, 122, 135, 142, 162, 173, 181, 190, 196, 202, 210, 215, 221, 245, 272, 277, 293 and 297 compared to the control sequence . Preparation of resistant test vectors and phenotypic analysis of patient 014397 HIV samples
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 014397. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-014397. RTV-014397 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • PDS patient derived segment
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV-014397 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-014397 mutations were noted at HIV RT codons 31, 102, 103, 123, 162, 166, 177, 211, 215, 228, 245, 272 and 277 compared to the control sequence .
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 013415. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-013415. RTV-013415 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • PDS patient derived segment
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • a pattern of susceptibility to the NNRTIs was observed for patient RTV-013415 in which there was a significant decrease in efavirenz (>450-fold) , nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility and a significant drug-dependent stimulation of viral replication in the presence of nevirapine (-20%) , delavirdine (-30%) and efavirenz (-20%) .
  • RTV-013415 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-013415 mutations were noted at HIV RT codons 35, 102, 103, 122, 123, 135, 162, 177, 200, 207, 211, 225, 245, 264, 277 and 290 compared to the control sequence.
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 10829. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-010829. RTV-010829 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • PDS patient derived segment
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for the resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • RTV-010829 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-010829 mutations were noted at HIV codons 31, 35, 90, 102, 103, 122, 162, 196, 211, 214, 215, 228, 245, 270, 276, 277, 292, 293 and 297 compared to the control sequence .
  • HIV-1 HIV Sequence Database Los Alamos, NM
  • the RTV-010829/245V showed drug-dependent stimulation of viral replication in the presence of nevirapine (-80%) , efavirenz (-60%) and delavirdine
  • RTV-010829/270I was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-010829.
  • the RTV-010829/270I displayed high-level reductions in susceptibility to nevirapine (341-fold) , efavirenz (145-fold) and delavirdine (247-fold) compared to a wild type control RTV.
  • the RTV-010829/245V showed drug-dependent stimulation of viral replication in the presence of nevirapine (-30%) , efavirenz (-20%) and delavirdine
  • a resistance test vector containing all of the mutations present in RTV-010829 except for V245E, I270M, V276I, R277K, V292I, V293I and E297K (RTV-010829/245V-
  • 010829/245V-297E displayed high-level reductions in susceptibility to nevirapine (233-fold) , efavirenz (76- fold) and delavirdine (198-fold) compared to a wild type control RTV.
  • the RTV-010829/245V-297E showed no drug- dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine.
  • drug-dependent stimulation of viral replication is modulated by the presence of the mutations V245E and I270M.
  • Drug-dependent stimulation of viral replication can be completely abrogated by reversion of mutations V245E, I270M, V276I, R277K, V292I, V293I and E297K.
  • a resistance test vector was constructed as described in Example 1 from a virus sample obtained from patient 013522. The prior and current treatment regimens are unknown. Isolation of viral RNA and RT/PCR was used to generate a patient derived segment (PDS) that comprised viral sequences coding for all of PR and aa 1 - 313 of RT from all three samples. The PDS were inserted into an indicator gene viral vector to generate a resistance test vector designated RTV-013522. RTV-013522 was then tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs. This panel of anti-retroviral drugs comprised members of the classes known as NRTIs
  • IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility.
  • a pattern of susceptibility to the NNRTIs was observed for patient RTV-013522 in which there was a sigificant decrease in efavirenz (>450-fold) , nevirapine (>600-fold) and delavirdine (>250-fold) susceptibility and a significant drug-dependent stimulation of viral replication in the presence of nevirapine (-90%) , delavirdine (-110%) and efavirenz (-100%) .
  • RTV-013522 DNA was analyzed by ABI chain terminator automated sequencing. The nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) . The genotype was examined for sequences that are different from the control sequence. In RTV-013522 mutations were noted at HIV RT codons 35, 60, 68, 102, 103, 135, 162, K166R, 184, 196, 204, 211, 248, 250, 270, 286, 293 and 297 compared to the control sequence.
  • HIV-1 HIV Sequence Database Los Alamos, NM
  • Site directed revese-mutagenesis is used to confirm the role of specific mutations in phenotypic susceptibility to anti-retroviral drugs in HIV
  • a resistance test vector containing all of the mutations present in RTV-010829 except for the I270S was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-013522.
  • the RTV-013522/270I displayed moderate reductions in nevirapine (14-fold) and efavirenz (8-fold) susceptibility and a significant reduction in delavirdine (40-fold) susceptibility compared to a wild type control RTV.
  • the RTV-013522/270I showed no drug-dependent stimulation of viral replication in the presence of any of the NNRTI tested. In this patient sample the correlation of drug-dependent stimulation of viral replication with the mutation at I270S is very striking.
  • a resistance test vector containing a single mutation at I270S (RTV-I270S) was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a wild type control RTV.
  • the RTV- I270S showed small reductions in susceptibility to nevirapine (15-fold) , efavirenz (4-fold) and delavirdine (13 -fold) compared to a wild type control RTV.
  • the RTV- I270S showed drug-dependent stimulation of viral replication in the presence of nevirapine (-60%) , delavirdine (-60%) and efavirenz (-40%) .
  • a resistance test vector containing a single mutation, V245E, (RTV-V245E) was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at position 245.
  • RTV-V245E was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at position 245.
  • the RTV-V245E displayed no reductions in susceptibility to nevirapine, efavirenz or delavirdine compared to a wild type control RTV.
  • the RTV-V245E showed no drug-dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine.
  • a resistance test vector containing a single mutation, V245T, (RTV-V245T) was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at position 245.
  • RTV-V245E The RTV-V245T displayed no reductions in susceptibility to nevirapine, efavirenz or delavirdine compared to a wild type control RTV.
  • the RTV-V245T showed no drug-dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine . I135T
  • a resistance test vector containing a single mutation, I135T, (RTV-I135T) was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at position 135.
  • RTV-I135T displayed no reductions in susceptibility to nevirapine, efavirenz or delavirdine compared to a wild type control RTV.
  • the RTV-I135T showed no drug-dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine .
  • a resistance test vector containing a single mutation, K103N, (RTV-K103N) was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 103.
  • the RTV-K103N displayed reductions in susceptibility to nevirapine (67-fold) , efavirenz (29-fold) and delavirdine (87-fold) compared to a wild type control RTV.
  • the RTV-K103N exhibited no drug-dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine.
  • a resistance test vector containing two mutations, K103N and I135T was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at position 103 and 135.
  • the RTV-K103N/I135T displayed reductions in susceptibility to nevirapine (171-fold) , efavirenz (80-fold) and delavirdine (121- fold) compared to a wild type control RTV.
  • the RTV- K103N/I135T exhibited no drug-dependent stimulation of viral replication in the presence of nevirapine, efavirenz, or delavirdine.
  • a resistance test vector containing two mutations, I135T and V245E was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at positions
  • RTV-I135T/V245E The RTV-I135T/V245E displayed minor reductions in susceptibility to nevirapine (2.5-fold), efavirenz (2-fold) and delavirdine
  • a resistance test vector containing two mutations, I135T and V245T was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 135 and 245.
  • the RTV-I135T/V245T displayed minor reductions in susceptibility to nevirapine (4-fold), efavirenz (2.4-fold) and delavirdine
  • I135T/V245T exhibited no drug-dependent stimulation of viral replication in the presence of efavirenz and only minor stimulation of viral replication in the presence of nevirapine (-10%) or delavirdine (-10%) .
  • a resistance test vector containing three mutations, K103N, I135T and V245T was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 103, 135 and 245. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in RTV-K103N.
  • the RTV-K103N/I135T/V245T displayed significant reductions in susceptibility to nevirapine (594-fold) , efavirenz (174-fold) and delavirdine (>250- fold) compared to a wild type control RTV.
  • the RTV- K103N/I135T/V245T showed drug-dependent stimulation of viral replication in the presence of efavirenz (-25%) , nevirapine (-40%) and delavirdine (-50%) .
  • Resistance test vectors were constructed as described in Example 1 from virus samples obtained from an individual patient at thirteen separate time points over a 2%-year period. This patient had been previously treated with two NRTIs (zidovudine and lamivudine) AZT, 3TC (NRTIs) , 106
  • a resistance test vector containing three mutations, K103N, I135T and V245E was constructed and tested in the phenotypic assay described earlier. The results were compared to those determined using a genetically defined resistance test vector that was wild type at positions 103, 135 and 245. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in RTV-K103N.
  • the RTV-K103N/I135T/V245E displayed reductions in susceptibility to nevirapine (244-fold) , efavirenz (93 -fold) and delavirdine (169-fold) compared to a wild type control RTV.
  • the RTV-K103N/I135T/V245E showed no drug-dependent stimulation of viral replication in the presence of efavirenz but showed moderate levels of viral stimulation of replication in the presence of nevirapine (-15%) and delavirdine (-20%) .
  • a PRI inavir
  • the patient began taking a new anti-viral regimen including an NRTI (stavudine) , an NNRTI (nevirapine) , and two PRIs (nelfinavir and saquinavir) at the time the third sample (98-1032) was obtained. Additional samples were obtained 4, 5 and 10 weeks later (00-2-011658, 00-2-011659 and 98-1033, respectively) .
  • RTVs were tested in a phenotypic assay to determine accurately and quantitatively the level of susceptibility to a panel of anti-retroviral drugs.
  • This panel of anti-retroviral drugs comprised members of the classes known as NRTIs zidovudine, lamivudine, stavudine, didanosine, zalcitabine, and abacavir) NNRTIs (delavirdine, efavirenz and nevirapine) , and PRIs (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) .
  • An IC50 was determined for each resistance test vector pool for each drug tested. The pattern of susceptibility to all of the drugs tested was examined and compared to known patterns of susceptibility. A pattern of susceptibility to the
  • NNRTIs was observed for patient RTV-1033, RTV- 008973, RTV-757, RTV-008980 and RTV-1080 in which there were reductions in nevirapine (>600-fold) , delavirdine (from 3 to 18 -fold) and efavirenz (from 16 to 300 fold) susceptibility. Furthermore, RTV-1033, RTV-008973, RTV- 757, RTV-008980 and RTV-1080 showed drug-dependent stimulation of viral replication in response to nevirapine (40 to 250%) , delavirdine (20 to 180%) and efavirenz (30 to 170%) . The actual fold change in susceptibility and the percent stimulation of viral replication for each RTV is shown in Figure 14a.
  • RTV-309, RTV-754, RTV-1032, RTV-011658, RTV-011659, RTV- 1033, RTV-008973, RTV-757, RTV-008980, RTV1080, RTV1264 and RTV-006174 DNA were analyzed by ABI chain terminator automated sequencing.
  • the nucleotide sequence was compared to the consensus sequence of a wild type clade B HIV-1 (HIV Sequence Database Los Alamos, NM) .
  • the genotype was examined for sequences that are different from the control sequence. Mutations were observed at the positions listed in Figure 14b.
  • Site directed mutagenesis is used to confirm the role of specific mutations in phenotypic susceptibility to antiretroviral drugs in HIV RTV-1033 displayed the most dramatic drug-dependent stimulation of viral replication of all of the samples tested from this patient.
  • a single clone (RTV-1033 -3) was obtained from the patient-derived RTV pool that had mutations and phenotypic patterns of NNRTI susceptibility and drug-dependent stimulation of viral replication characteristic of the RTV-1033 pool.
  • the RTV-1033 -3 had the following mutations present in the revere transcriptase: V35I, D67N, T69D, K70R, V106A, D123G, V189L, T200A, I202T, H208Y, R211K, T215F, D218E, K219Q, H221Y, L228H, L283I, R284K, T286A, V293I and E297K.
  • RTV- 1033 -3 showed dramatic reductions in susceptibility to delavirdine (27-fold) , efavirenz (>450-fold) and nevirapine (>600-fold) and dramatic drug-dependent stimulation of viral replication in the presence of delavirdine (190%) , efavirenz (180%) and nevirapine (200%) .
  • a resistance test vector containing all of the mutations present in RTV-1033 -3 except for V106A was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-1033-3. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in the reverted vector, RTV-1033-3/106V.
  • the RTV-1033-3/106V displayed a moderate reduction in nevirapine (9-fold) susceptibility, no reduction in efavirenz susceptibility and a significant increase in delavirdine (20-fold) susceptibility (hyper-susceptibility) compared to a wild type control RTV.
  • the RTV-1033 -3/106V showed no drug- dependent stimulation of viral replication in the presence of delavirdine but showed low levels of drug- dependent stimulation of viral replication in the presence of efavirenz (-20%) and nevirapine (-40%) .
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for F227L was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-1033-3.
  • the RTV-1033-3/227F displayed significant reductions in nevirapine (>600-fold) , efavirenz (18-fold) and delavirdine (72-fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033 -3/227F showed drug-dependent stimulation of viral replication in the presence of delavirdine (-100%) , efavirenz (-100%) and nevirapine (-120%) .
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for V106A and F227L (RTV-
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for V106A, V189L and F227L was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV- 1033-3.
  • the RTV-1033 -3/106V/189V/227F displayed small reductions in nevirapine (2.8-fold), efavirenz (2-fold) and delavirdine (2.7-fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033-3/106V/189V/227F showed drug-dependent stimulation of viral replication in the presence of delavirdine (-35%) , efavirenz (-30%) and nevirapine (-40%) .
  • V106A, F227L and T286A V106A, F227L and T286A
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for V106A, F227L and T286A was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV- 1033-3. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in the reverted vector, RTV-1033- 3/106V/227F/286T.
  • the RTV-1033-3/106V/227F/286T displayed moderate reductions in nevirapine (6-fold) , efavirenz (5-fold) and delavirdine (3 -fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033-3/106V/227F/286T showed drug-dependent stimulation of viral replication in the presence of delavirdine (-60%) , efavirenz (-50%) and nevirapine (-70%) .
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for L283I, R284K and T286A was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV- 1033-3. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in the reverted vector, RTV-1033- 3/283L/284R/286T.
  • the RTV-1033-3/283L/284R/286T displayed significant reductions in nevirapine (>600- fold) , efavirenz (85-fold) and delavirdine (7-fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033-3/283L/284R/286T showed drug-dependent stimulation of viral replication in the presence of delavirdine (-40%) , efavirenz (-30%) and nevirapine (-80%) .
  • a resistance test vector containing all of the mutations present in RTV-1033-3 except for L283I, R284K, T286A, V293I and E297K was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-1033-3.
  • the RTV- 1033-3/283L/284R/286T/293V/297E displayed significant reductions in nevirapine (144-fold) , efavirenz (5-fold) and delavirdine (16 -fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033- 3/283L/284R/286T/293V/297E showed no drug-dependent stimulation of viral replication in the presence of delavirdine, efavirenz or nevirapine.
  • a resistance test vector containing all of the mutations present in RTV-1033-3, in addition to Y181C (RTV-1033- 3/181C) was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-1033-3.
  • the RTV-1033-3/181C displayed a significant reduction in nevirapine (>600- fold) , efavirenz (>450-fold) and delavirdine (>250-fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033-3/181C showed no drug-dependent stimulation of viral replication in the presence of nevirapine but showed drug-dependent stimulation of viral replication in the presence of efavirenz (-100%) and nevirapine (-100%)
  • Ml84V A resistance test vector containing all of the mutations present in RTV-1033-3 in addition to M184V (RTV-1033- 3/184V) was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-1033-3. We determined the pattern of phenotypic susceptibility to the NNRTIs, delavirdine, nevirapine and efavirenz, in the mutated vector, RTV-1033-3/184V.
  • the RTV-1033-3/184V displayed a significant reduction in nevirapine (>600- fold) , efavirenz (28 -fold) and a moderate reduction in delavirdine (5-fold) susceptibility compared to a wild type control RTV.
  • the RTV-1033 -3/184V showed drug-dependent stimulation of viral replication in the presence of delavirdine (100%) , efavirenz (-80%) and nevirapine (-100%) .
  • RTV-309 was derived from a virus sample from patient 1033 before the patient had received any NNRTI inhibitors.
  • RTV-309 exhibited a wild type pattern of susceptibility to delavirdine and efavirenz and a small reduction in susceptibility to nevirapine (3 -fold) and no drug- dependent stimulation of viral replication in the presence of NNRTIs.
  • a single clone (RTV-309-3) was obtained from the patient-derived RTV pool that had mutations and phenotypic patterns of NNRTI susceptibility and drug-dependent stimulation of viral replication characteristic of the RTV-1033 pool.
  • the RTV-309-3 had the following mutations present in the revere transcriptase: V35I, D67N, T69D, K70R, L109I, M184V, V189L, T200A, I202T, H208Y, R211K, T215F, D218E, K219Q, H221Y, L228H, L283I, R284K, T286A and E297K.
  • RTV-309-3 exhibited a wild type pattern of susceptibility to delavirdine and efavirenz and a small reduction in susceptibility to nevirapine (3 -fold) and no drug- dependent stimulation of viral replication in the presence of NNRTIs.
  • a resistance test vector containing all of the mutations present in RTV-309-3 except for the Ml84V was constructed and tested using the phenotypic assay described earlier. The results were compared to those determined using the parent RTV-309-3.
  • the RTV-309-3/184M displayed a moderate reduction in delavirdine (4-fold) , efavirenz (5-fold) and nevirapine (9-fold) susceptibility compared to a wild type control RTV.
  • the RTV-309-3/184M showed drug-dependent stimulation of viral replication in the presence of delavirdine (-50%) , efavirenz (-60%) and nevirapine (-80%) .
  • the invention further relates to novel vectors, host cells and compositions for isolation and identification of the non-nucleoside HIV-1 reverse transcriptase inhibitor resistance mutant and using such vectors, host cells and compositions to carry out anti-viral drug screening.
  • This invention also relates to the screening of candidate drugs for their capacity to inhibit/stimulate said mutant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des essais de résistance et de susceptibilité aux médicaments antiviraux destinés à être utilisés pour l'identification de régimes posologiques efficaces dans le traitement de l'infection par le virus de l'immunodéficience humaine (VIH) et du syndrome d'immunodéficience acquis (SIDA). L'invention concerne en outre des systèmes et des procédés pour le contrôle de la progression clinique de l'infection par le VIH et de sa réponse à la thérapie antirétrovirale, en particulier la thérapie par inhibiteur de transcriptase inverse de nucléoside fondée sur des essais de susceptibilité phénotypique ou des essais génotypiques.
PCT/US2001/018882 2000-06-12 2001-06-12 Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida WO2001096611A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR0111575-8A BR0111575A (pt) 2000-06-12 2001-06-12 Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
AU2001266863A AU2001266863A1 (en) 2000-06-12 2001-06-12 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
JP2002510724A JP2004503253A (ja) 2000-06-12 2001-06-12 Ｈｉｖ／ａｉｄｓ療法における抗レトロウイルス療法のモニタリングおよび治療決定をガイドするのための手段および方法
CA002411401A CA2411401A1 (fr) 2000-06-12 2001-06-12 Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida
EP01944452A EP1292712A4 (fr) 2000-06-12 2001-06-12 Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189400A 2000-06-12 2000-06-12
US09/591,894 2000-06-12

Publications (1)

Publication Number Publication Date
WO2001096611A1 true WO2001096611A1 (fr) 2001-12-20

Family

ID=24368395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018882 WO2001096611A1 (fr) 2000-06-12 2001-06-12 Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida

Country Status (8)

Country Link
EP (1) EP1292712A4 (fr)
JP (1) JP2004503253A (fr)
CN (1) CN1446265A (fr)
AU (1) AU2001266863A1 (fr)
BR (1) BR0111575A (fr)
CA (1) CA2411401A1 (fr)
WO (1) WO2001096611A1 (fr)
ZA (1) ZA200210003B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579143B2 (en) 1998-05-26 2009-08-25 Monogram Biosciences, Inc. Method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105647947A (zh) * 2015-12-30 2016-06-08 南方医科大学 一种转移质粒及其构建方法和重组慢病毒
CN105648037B (zh) * 2015-12-30 2020-06-05 南方医科大学 一种重组慢病毒在hiv表型耐药检测中的应用
WO2018045425A1 (fr) * 2016-09-07 2018-03-15 St Vincent's Hospital Sydney Limited Méthodes de détection de lentivirus
EP3649249A4 (fr) * 2017-07-04 2021-03-03 Cavidi AB Procédé d'évaluation de la sensibilité d'un virus à un traitement par mesure de l'activité enzymatique et système associé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917033A (en) * 1995-10-31 1999-06-29 University Of Medicine & Dentistry Of New Jersey Structure based design of inhibitors of HIV-1 reverse transcriptase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087093A (en) * 1996-01-26 2000-07-11 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
AU717755B2 (en) * 1996-01-26 2000-03-30 Virco Bvba Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains
CA2329140A1 (fr) * 1998-05-26 1999-12-02 Virologic, Inc. Procedes et moyens de surveillance de therapie antiretrovirale des inhibiteurs de transcriptase inverse des non-nucleosides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917033A (en) * 1995-10-31 1999-06-29 University Of Medicine & Dentistry Of New Jersey Structure based design of inhibitors of HIV-1 reverse transcriptase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1292712A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579143B2 (en) 1998-05-26 2009-08-25 Monogram Biosciences, Inc. Method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient

Also Published As

Publication number Publication date
BR0111575A (pt) 2003-06-24
CA2411401A1 (fr) 2001-12-20
EP1292712A1 (fr) 2003-03-19
CN1446265A (zh) 2003-10-01
ZA200210003B (en) 2004-12-22
JP2004503253A (ja) 2004-02-05
EP1292712A4 (fr) 2005-04-20
AU2001266863A1 (en) 2001-12-24

Similar Documents

Publication Publication Date Title
US5837464A (en) Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
EP0852626B1 (fr) Compositions et procedes pour determiner la sensibilite et la resistance vis-a-vis de medicaments antiviraux et criblage de medicaments antiviraux
US6653081B2 (en) Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS
US20110229906A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
WO2000078996A9 (fr) Moyens et methodes pour surveiller un traitement antiretroviral utilisant un inhibiteur de la protease et pour aider a la prise de decisions therapeutiques concernant le traitement du vih/sida
AU772511B2 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
US7138231B2 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CA2422815A1 (fr) Moyens et methodes de suivi d'une therapie antiretrovirale a base d'inhibiteurs de proteases et decisions d'orientation therapeutique dans le traitement du vih et du sida
EP1292712A1 (fr) Systemes et procedes pour le controle de therapie antiretrovirale et l'orientation des decisions therapeutiques dans le traitement du vih/sida
US6869759B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7579143B2 (en) Method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on a human immunodeficiency virus type 1 (HIV-1)-infected patient
US7186506B1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP2522757A1 (fr) Procédés et compositions permettant de déterminer la sensibilité à un médicament anti-VIH et la capacité de réplication du VIH
US20050130134A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment HIV-AIDS
US20020094522A1 (en) Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2007231808A1 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002/10003

Country of ref document: ZA

Ref document number: 200210003

Country of ref document: ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 510724

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2411401

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001944452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018140564

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001944452

Country of ref document: EP